289677-11-8

Basic information

• Product Name: (R)-4-BENZYL-3-(3-CYCLOPROPYL-PROPIONYL)-OXAZOLIDIN-2-ONE
• Synonyms: (R)-4-BENZYL-3-(3-CYCLOPROPYL-PROPIONYL)-OXAZOLIDIN-2-ONE;3-(3-CYCLOPROPYL-1-OXOPROPYL)-4(R)-(1-PHENYLMETHYL)-2-OXAZOLIDINONE;3-(3-CYCLOPROPYL-1-OXOPROPYL)-4(R)-(1-;2-Oxazolidinone, 3-(3-cyclopropyl-1-oxopropyl)-4-(phenylmethyl)-, (4R)-
• CAS NO: 289677-11-8
• Molecular Formula: C16H19NO3
• Molecular Weight: 273.33
• Mol File: 289677-11-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 446.4°Cat760mmHg
• Flash Point: 223.8°C
• Appearance: /
• Density: 1.227g/cm³
• Vapor Pressure: 3.66E-08mmHg at 25°C
• Refractive Index: 1.578
• CAS DataBase Reference: (R)-4-BENZYL-3-(3-CYCLOPROPYL-PROPIONYL)-OXAZOLIDIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-BENZYL-3-(3-CYCLOPROPYL-PROPIONYL)-OXAZOLIDIN-2-ONE(289677-11-8)
• EPA Substance Registry System: (R)-4-BENZYL-3-(3-CYCLOPROPYL-PROPIONYL)-OXAZOLIDIN-2-ONE(289677-11-8)

Safety Data

• Hazardous Substances Data: 289677-11-8(Hazardous Substances Data)

Usage

General Description

(R)-4-Benzyl-3-(3-cyclopropyl-propionyl)-oxazolidin-2-one, also known as Pregabalin, is a medication used to treat neuropathic pain, epilepsy, and generalized anxiety disorder. It is a central nervous system depressant that works by binding to calcium channels in the central nervous system, which reduces the release of neurotransmitters. Pregabalin is a derivative of gamma-aminobutyric acid (GABA), but it does not directly affect GABA receptors. It is available in various forms, including capsules, and is typically taken orally. Side effects may include dizziness, drowsiness, and weight gain. Due to its potential for abuse and addiction, it is classified as a controlled substance in some jurisdictions.

InChI:InChI=1/C16H19NO3/c18-15(9-8-12-6-7-12)17-14(11-20-16(17)19)10-13-4-2-1-3-5-13/h1-5,12,14H,6-11H2/t14-/m1/s1

Upstream product

• 5618-03-1 3-cyclopropanepropionic acid 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 101711-90-4 (S)-4-benzyl-2-oxazolidinone lithium salt 
• 186581-53-3 diazomethane 
• 104266-88-8 (4S)-4-benzyl-3-pent-4-enoyl-1,3-oxazolidin-2-one 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS

The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties

A systematic examination of the central aromatic portion of the lead (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(1′H-spiro[indene-1,4′-piperidin]-1′-yl)butanamide (9) led to the discovery of a novel class of CCR2 receptor antagonists, which carry small alicyclic groups such as cyclopropyl, cylobutyl, or cyclopropylmethyl attached at C2 of the carbon backbone. The most potent compound discovered, namely (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-cyclopropyl-4-[(1R,3′R)-3′-methyl-1′H-spiro[indene-1,4′-piperidin]-1′-yl]butanamide (29), showed very high binding affinity (IC50 = 4 nM, human monocyte) and excellent selectivity toward other related chemokine receptors. The excellent pharmacokinetic profile of this new lead compound allows for extensive in vivo evaluation.

RENIN INHIBITING POLYHYDROXY-MONOAMIDES

Disclosed herein are compounds of the formula:R 1 CH 2 CH(X)CH(Y)CH(Z)CHR 2 C(O)NHCHR 3 CH(OH) CH(OH)R 4wherein R 1 is a terminal unit, for example lower cycloalkyl or phenyl; R 2 is, for example, an optionally substituted alkyl, cycloalkylme